1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
MRD Testing Market - A Global and Country Analysis: Focus on Technology, Application, End User, Region - Analysis and Forecast, 2022-2027

MRD Testing Market - A Global and Country Analysis: Focus on Technology, Application, End User, Region - Analysis and Forecast, 2022-2027

  • June 2022
  • 281 pages
  • ID: 6285551
  • Format: PDF
  • BIS Research


Table of Contents

Global Minimal Residual Disease (MRD) Testing Market to Reach $2,611.2 Million by 2027

Global MRD Testing Market: Industry Overview

The minimal residual disease (MRD) testing market is projected to reach $2,611.2 million by 2027 from $1,089.3 million in 2021, at a CAGR of 14.53%. The market is driven by certain factors, such as the rising incidence of hematologic malignancies, increasing consumer awareness for tailored therapy, increasing research funding from the National Cancer Institute and increasing disposable income in emerging economies.

Market Lifecycle Stage

The global MRD testing market is in the rapidly evolving and dynamic stage, which opens ample opportunities for diagnostic and life science companies. Also, companies that are already in the development phase for MRD tests are trying to match themselves with modern technologies in the market to improve the overall system of MRD testing, from diagnostic assays and kits development to commercialization. The companies operating in the global MRD testing market are now focusing more on disease-specific and personalized diagnostic kits to enhance testing and improve detection outcomes. Also, major players such as ARUP Laboratories, Adaptive Biotechnologies Corporation, Bio-Rad Laboratories, Inc., Cergentis B.V, F. Hoffmann-La Roche Ltd, and Guardant Health are investing heavily in research and development for their respective testing products.


With an increased worldwide focus on treating hematological malignancies, the major market players are developing novel diagnostic tests, which are significantly impacting the growth of the MRD testing market. Diagnostic evolution in the form of companion diagnostics and liquid biopsy through molecular techniques such as PCR and NGS has enabled molecular diagnostic juggernauts to enter this market seamlessly. Following FDA approvals of clonoSEQ and Signatera, major companies are now looking to invest in the field of MRD, focusing primarily on the foundation laid for hematological malignancies. The market witnessed approximately 35 significant synergistic developments during the time period between January 2018 and May 2022.

In addition to this, in November 2021, Palmetto GBA’s Molecular Diagnostics Program (MolDX) has confirmed a local coverage determination that supported the Medicare coverage for Adaptive Biotechnologies clonoSEQ in patients with B-cell acute lymphoblastic leukemia (ALL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL) for monitoring minimal residual disease. The above activities created a global impact and contributed to an increase in MRD testing market.

Market Segmentation

Segmentation 1: by Technology
• Flow Cytometry
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Other Technologies

Due to recent developments in molecular diagnostic technologies, the turnaround time and overall cost have been reduced with increased sensitivity and accuracy of results. Significant advances are being witnessed in the development of highly sensitive, quantitative, and multiplex assays. Some of the new technologies include NGS and low-cost PCR devices available in the form of multiparameter assays and multiplexing devices for MRD testing.

Segmentation 2: by Application
• Hematological Malignancy
• Solid Tumor

The global MRD testing market (by application) is broadly segmented into hematological malignancy and solid tumor applications. The global MRD testing market (by application) is dominated by hematological malignancy, which held a share of 94.39% in 2021.

Segmentation 3: by End User
• Hospital and Specialty Clinics
• Diagnostic Laboratories
• Research Institutions
• Other End Users

End users of the MRD market typically include hospitals and specialty clinics, research institutions, diagnostic laboratories, and others. Although hospitals and specialty clinics have been at the forefront of developing advanced technologies that incorporate several ancillaries for superior biological and chemical research, the applicability of MRD tests has been widespread among research institutions. Other end users, such as out-patient clinics and cancer clinics, also contribute significantly to the global MRD testing market.

Segmentation 4: by Region
• North America
o U.S.
o Canada
• Europe
o Germany
o Italy
o France
o U.K.
o Spain
o Rest-of-Europe
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Australia
o Singapore
o Rest-of-APAC (RoAPAC)
• Latin America and Middle East
o Brazil
o Mexico
o Saudi Arabia
o Rest-of-Latin America and Middle East
• Rest-of-the-World (RoW)

In 2021, North America accounted for a share of 42.92% of the global minimal residual disease testing market. The segment is expected to reach $1,016.8 million in 2027 from $467.5 million in 2021 at a CAGR of 12.68% during the forecast period 2022-2027.

Recent Developments in the Global MRD Testing Market

• In November 2021, Palmetto GBA’s Molecular Diagnostics Program (MolDX) confirmed a local coverage determination that supported the Medicare coverage for clonoSEQ in patients with B-cell acute lymphoblastic leukemia (ALL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL) for monitoring minimal residual disease.
• In February 2021, Natera, Inc. and Personalis, Inc. partnered in the field of personalized oncology by combining Personalis’ NeXT tumor profiling and diagnostic products with Natera’s personalized ctDNA platform Signatera for treatment monitoring and molecular residual disease assessment.
• In May 2021, Invivoscribe, Inc. announced licensing of key software and two new MRD clinical services. The company’s LymphoTrack Enterprise Software supported high volume customers to meet ever-increasing testing demands.
• In October 2021, Inivata Limited, a subsidiary of NeoGenomics, Inc. entered a clinical collaboration with the Princess Margaret Cancer Center in Toronto, Canada, for the use of Inivata’s InVisionFirst-Lung and RaDaR liquid biopsy assays in two separate studies.

Demand – Drivers and Limitations

Following are the demand drivers for the global MRD testing market:

• Rising Incidence of Hematological Malignancies
• Increasing Consumer Awareness for Tailored Therapy
• Increase in Research Funding from National Cancer Institute
• Increasing Disposable Income in Emerging Economies

The market is expected to face some limitations too due to the following challenges:

• False Negatives and Positives
• Uncertain Reimbursement and Regulatory Policies
• Lack of Trained Professionals
• Lack of Established Treatment Protocols for High-Value Tests in Emerging Economies

How can this report add value to an organization?

Technology/Innovation Strategy: The technology segment helps the reader understand the different technology based on MRD testing present in the market. Moreover, the study provides the reader with a detailed understanding of two different applications including hematologic malignancy and solid tumor.

Growth/Marketing Strategy: The global MRD testing market has seen major development by key players operating in the market, such as synergistic activities, product approvals, product launches and updates, mergers and acquisitions, business expansion and funding, and other developments (Medicare coverage). The favored strategy for the companies has been regulatory and legal activities along with product approvals to strengthen their position in the market.

Competitive Strategy: Key players in the global MRD testing market have been analyzed and profiled in the study. Moreover, a detailed competitive benchmarking of players operating in the global MRD testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Total Number of Companies Profiled: 15 (11 public companies and 4 private companies)

Public companies include ICON plc, Bio-Rad Laboratories, Inc., Adaptive Biotechnologies Corporation, Sysmex Corporation, Quest Diagnostics Incorporated, Opko Health, Inc., NeoGenomics Laboratories, Inc., Natera, Inc., Laboratory Corporation of America Holdings, F. Hoffmann-La Roche, and Guardant Health. The private company profiled are ARUP Laboratories, Cergentis B.V., Invivoscribe, Inc., and Mission Bio, Inc.

Countries Covered
. North America
. U.S.
. Canada
. Latin America and Middle East
. Brazil
. Mexico
. Saudi Arabia
. Rest-of-Latin America and Middle East
. Europe
. Germany
. Italy
. France
. U.K.
. Spain
. Rest-of-Europe
. Asia-Pacific
. Japan
. China
. India
. Australia
. South Korea
. Singapore
. Rest-of-Asia-Pacific
. Rest-of-the-World (RoW)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

2022 What’s Next for Bolivia Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests

  • $ 4500
  • August 2022

2022 What’s Next for Bolivia Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of ...

  • Bolivia
  • Diagnostics
  • Infectious Disease
  • Industry analysis


Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on